UM-UC-1 (Human bladder transitional cell carcinoma) cell line

UM-UC-1 was isolated from a human transitional cell carcinoma (grade II) originating from a bladder cancer metastasis (lymph) of a 26-year old black male.

Contributors

Inventor Institute
H. Grossman ; Anita Sabichi University of Michigan
Cat. #: 160436
Tool sub type: 10XUAS IVS p10
Unit size: 1×10^6 cells / vial
Cancer types: Genitourinary cancer;Genitourinary cancer
Research Fields: Cancer;Cancer
Organism: Human
Tissue: Lymphatic Tissue
Gender: Male
Model: Tumourigenic cell line
Growth properties: Adherent
Cancer Types In Detail: Human bladder translational cell carcinoma;Human bladder translational cell carcinoma
Alternate name: UM-UC-1; UMUC1; University of Michigan-Urothelial Carcinoma-1
Product description: UM-UC-1 is a well-characterised human urothelial carcinoma cell line derived from lymphatic metastases of grade II transitional cell carcinoma from a 26-year old male patient. This tumorigenic cell line demonstrates rapid tumour formation in nude mice (1-1.5cm diameter in <3 weeks) and exhibits strong p53 nuclear overexpression by IHC analysis. This cell line has a high level of coxsackie adenovirus receptor. UM-UC-1 was more resistant to adenoviral gene transduction than several of the other cells evaluated. UM-UC-1 is part of the comprehensive 11 cell UM-UC panel deposited by the university of Michigan
Gender: Male
CRISPR: Yes
Conditional: Yes
disease: Cancer;Cancer
Format: Frozen
Shipping conditions: Dry ice
Growth medium: Cells were grown in MEM + 1% NEAA + 2mM Glutamine + 10% Foetal Bovine Serum (FBS).
Subculture routine: Split sub confluent cultures (70-80%) 1:4 to 1:10 i.e. seeding at 2-4×10,000 cells/cm2; using 0.05% trypsin or trypsin/EDTA; 5% CO2, 37°C. Doubling time approximately 26 hours.
Mycoplasma free: Yes
References:

Grossman et al. 1984. J Urol. 132(4):834-7. PMID: 6471236.

Grossman et al. 1986. J Urol. 136(5):953-9. PMID: 3761468.

Sabichi et al. 2006. J Urol. 175(3 Pt 1):1133-7. PMID: 16469639.

Park et al. 2008. J Natl Cancer Inst. 100(19):1401-11. PMID: 18812553.

Chiong et al. 2009. J Urol. 181(6):2737-45. PMID: 19375735.

Barretina et al. 2012. Nature. 483(7391):603-7. PMID: 22460905. Guo et al. 2013. J Pathol. 230(1):17-27. PMID: 23401075.

Klijn et al. 2015. Nat Biotechnol. 33(3):306-12. PMID: 25485619.

Yu et al. 2015. Nature. 520(7547):307-11. PMID: 25877200.

Earl et al. 2015. BMC Genomics. 16:403. PMID: 25997541.

Scholtalbers et al. 2015. Genome Med. 7:118. PMID: 26589293.

Nickerson et al. 2017. Oncogene. 36(1):35-46. PMID: 27270441.

Zuiverloon et al. 2018. Bladder Cancer. 4(2):169-83. PMID: 29732388.

Dutil et al. 2019. Cancer Res. 79(6):1263-73. PMID: 30894373.

Ghandi et al. 2019. Nature. 569(7757):503-8. PMID: 31068700.

Images

View Gallery
UM-UC-1 Cell Line - growth profile. Image courtesy of the European Collection of Authenticated Cell Cultures (ECACC)

Citations And Reviews

Related Tools for Cell lines

Cat. # Tool Name
151445 1-7HB2 Cell Line Key Info View Tool
151479 HCT 116 p300 KO [D10] Cell Line Key Info View Tool
151488 B6.1.1 Mouse ES Cell Line Key Info View Tool
151558 MEF Trex1 KO Cell Line Key Info View Tool
151579 U-2 OS Gal4-p300 Cell Line Key Info View Tool

Related News

UM-UC-10 Cell Line. Image courtesy of the European Collection of Authenticated Cell Cultures (ECACC), UK.
Cell Lines

Popular cell lines now available only from CancerTools.org

Read More
Cell Lines

New cell lines: murine melanocyte and melanoblast cell lines from Dr. Elena Sviderskaya

Read More
Image Reference: 2x PTEN -/- mouse prostate cancer cell lines (MuCap system). Histology staining of syngraft tumours (Van Duijn et al., 2018).
Cell Lines

38 new prostate cancer cell lines

Read More

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.